Jerome Castellano

Biosimilar reimbursement rates are driving infusion practices toward financial losses.

Payer behavior, not internal operations, now drives infusion revenue loss.

Payer policy shifts now pose bigger revenue risks than staffing for infusion platforms.

How to avoid the five most expensive J-code mistakes that tank biologic claims.